THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era Thursday, March 5, 2026

COMPOUND WATCH

Orforglipron [Phase 3] — The structural story of the week. ACHIEVE-3 data in The Lancet: 9.2% weight loss at 52 weeks on 36mg vs. 5.3% for oral semaglutide 14mg. HbA1c reduction: 2.2% vs. 1.4%. Trial: 1,698 adults, 52 weeks. No food/timing restrictions — oral semaglutide requires empty stomach, ≤4oz water, 30-minute pre-meal wait. Projected cash-pay price per Metabolic Weekly: $149–$399/month (unconfirmed by Lilly; treat as analyst estimate until launch pricing is announced). The $149 floor is the number that matters — that's the price point that would undercut compounded tirzepatide at most 503A pharmacies. FDA decision: early Q2 2026. Lilly CFO confirmed at TD Cowen: able to ship within ~1 week of approval. $1.5B pre-launch inventory already staged. If approved at the low end of that price range, the premium that drives ~10M Americans to compounders compresses significantly.

Oral semaglutide (Wegovy pill) [Phase 3] — Launched in the U.S. in January 2026. First oral GLP-1 approved for obesity in the U.S. — six weeks old and already being compared unfavorably to orforglipron. Compliance burden: empty stomach, ≤4oz water, 30-minute pre-meal wait. If you're on injectable tirzepatide and considering a switch to oral, orforglipron's no-restriction protocol is the meaningful differentiator — not semaglutide vs. tirzepatide efficacy.

Tirzepatide [Phase 3] — New SURMOUNT-1 post-hoc data (n=690, 3 years continuous): mean weight regain from nadir only 3.7%. 73% of patients on 15mg regained <5%. Contrasted directly against this week's eClinicalMedicine systematic review (48 studies): patients who stopped GLP-1s regained ~60% of lost weight within 1 year; modeling suggests ~75% regain after >1 year off. Read those two data points together: the drug works while you take it, and stops working when you stop. That's not pharma spin — it's a 48-study meta-finding. Every person who starts a GLP-1 is a potential lifetime customer. This is why the market projects $70B → $201B.

CagriSema [Phase 3] — REDEFINE 4 results: CagriSema 2.4mg/2.4mg achieved 23.0% weight loss vs. 25.5% for tirzepatide 15mg at week 84 — failed non-inferiority primary endpoint. Under treatment-regimen estimand: 20.2% vs. 23.6%. NDA submitted December 2025; regulatory decision expected late 2026. For context on what's at stake: Lilly's tirzepatide franchise generated ~$36.5B in 2025 (>50% of total Lilly sales). Novo's obesity-care sales reached DKK 82.3B (~$12B USD) in 2025, up 31%. Novo's competitive position just got materially weaker — and those revenue figures show exactly how much ground they're defending.

Retatrutide [Phase 3] — TRIUMPH-4 (late 2025): 28.7% mean weight loss — the highest pharmacological obesity number ever recorded. TRIUMPH Phase 3 program (NCT07357415 now recruiting) has key readouts throughout 2026. If Phase 3 replicates, retatrutide makes tirzepatide look conservative.

MariTide (Amgen) [Phase 3] — MARITIME Phase 3 (NCT07104500) ongoing. Phase 2 showed ~20% weight reduction. No new data this week. This is the third major competitor to tirzepatide after orforglipron and retatrutide — the competitive landscape isn't a two-horse race. Watch for 2026 readouts.

Semaglutide / GLP-1 class — off-label signals [Phase 3] — New Cell Metabolism study: semaglutide repairs cartilage damage by reprogramming chondrocyte metabolism, with benefits independent of weight loss — both weight-loss and non-weight-loss groups showed repair. New AAN data (~11,000 per group): GLP-1 users were 48% less likely to start valproate, 42% less likely to start CGRP monoclonal antibodies, 35% less likely to start tricyclic antidepressants vs. topiramate users for migraine. If you're managing migraines alongside a GLP-1 protocol, this is the first large-scale comparative data suggesting your GLP-1 may be doing double duty — not a reason to start one, but worth mentioning to your neurologist if you're already on it.

BPC-157 [Animal] — Zero human RCTs. Still. RFK Jr. named it explicitly as a reclassification target. Policy signal only — no Federal Register notice. Don't reconstitute your vials differently today.

TB-500 / CJC-1295 / Ipamorelin / GHK-Cu / Thymosin Alpha-1 / Selank / Semax [Animal/Anecdotal] — All on the RFK candidate list. Same caveat: announcement ≠ rule. See Regulatory Radar.

VENDOR SIGNAL

No Finnrick rating changes, HPLC failures, or new Janoshik test results surfaced today. No vendor shutdowns or raids on research peptide vendors confirmed.

What DID surface: the FDA issued 30 warning letters to telehealth GLP-1 compounders on March 3. These specifically targeted telehealth platforms — not research peptide vendors. Primary violations: (1) claims implying sameness with FDA-approved products, (2) advertising compounded GLP-1s under the telehealth firm's own brand without disclosing the compounded nature. This is the second enforcement wave since September 2025. In six months, FDA has sent more warning letters than the entire preceding decade combined. Commissioner Makary's statement: "It's a new era."

If you're sourcing tirzepatide or semaglutide through a telehealth platform: No public list of the 30 recipients has been confirmed yet. To check: monitor FDA.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters (filter by date: March 3, 2026 onward) and watch for any compliance notice or pricing change communication from your platform. A warning letter doesn't mean immediate shutdown — but it does mean compliance costs and potential supply disruption within 30–60 days. If your platform goes quiet or reprices suddenly, that's the tell.

503B facilities: only 72 registered remain nationally (point-in-time count — we don't have a clean year-over-year trend in today's data, but the direction is consolidation, not growth). Know whether your pharmacy is 503A or 503B — the scrutiny level differs.

Research peptide vendors (QSC, Amino Asylum, Peptide Sciences) are not the current enforcement target. But enforcement climate affects gray-market risk tolerance across the board.

[COA Only] — Default grade for any vendor without independent third-party HPLC verification. Check finnrick.com before your next order.

15–20% of supplier COAs show discrepancies when independently verified. You are injecting this. Sourcing quality is safety data.

TRIAL TRACKER

NCT07437547 — BPC-157 for Acute Hamstring Muscle Strain [Phase 2 | Recruiting | Started Feb 2026] BPC-157's first registered human Phase 2 RCT in history. Narrow indication (hamstring strain), early stage, no data yet — but the trial's existence changes the regulatory conversation. You can no longer say BPC-157 has no human trial pathway. If you're in the target population, this is the only path to physician-supervised, quality-controlled BPC-157. Watch for interim safety data in 12–18 months.

NCT07357415 — Retatrutide Phase 3 in Obesity (Non-T2D) [Phase 3 | Recruiting | Started Jan 2026] 28.7% mean weight loss in TRIUMPH-4. This Phase 3 in non-diabetic obesity is now enrolling. If it replicates, retatrutide becomes the compound that makes tirzepatide look conservative. Relevant to anyone on tirzepatide wondering what comes next — and to anyone tracking whether Lilly's dominance extends through 2030.

NCT05669755 — REDEFINE 3: CagriSema Cardiovascular Outcomes [Phase 3 | Active, not recruiting] CagriSema just failed non-inferiority vs. tirzepatide on weight loss. REDEFINE 3 is Novo's remaining repositioning play — if CV outcomes data is strong, they have a story. If it underperforms there too, CagriSema's commercial viability is in serious question against a competitor generating $36.5B/year. Watch for interim readouts H2 2026.

THE ODDS

RFK Peptide Reclassification — The dominant signal. Still no rule. On February 27 (Joe Rogan), RFK Jr. stated he wants to move ~14 of 19 Category 2 peptides back toward compounding access. Projected timeline per Orion Peptides analysis: public comment period March–April 2026, final guidance May–June 2026. Candidate list: BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, Thymosin Alpha-1, Semax, Selank, GHRP-2, GHRP-6, Epitalon, DSIP, PT-141, and Hexarelin. Note: different industry sources list slightly different candidate sets — the Orion Peptides analysis is the most detailed available as of today. Five most likely to stay in Category 2: Melanotan II, AOD-9604, MOTS-C, PEG-MGF, Cathelicidin LL-37.

Critical caveat: NO Federal Register notice has been published. NO reclassification has occurred. This is a policy signal from a cabinet secretary on a podcast — not a regulatory action. Treat it as a 40–50% probability event. If you're stocking up on gray-market BPC-157 because "RFK said it's fine," you're trading on a podcast appearance, not a rule. Act when you see a Federal Register notice, not before.

Inflation — 80% probability, $115K volume traded (Polymarket) 80% odds inflation exceeds 3% in 2026. Your $300/month peptide habit is a discretionary health expense priced in depreciating dollars. Compounding pharmacy prices are sticky upward — expect 5–10% price increases at 503A/503B facilities by Q3 if inflation holds above 3%. Lock in subscription pricing where available. This is the most directly actionable macro signal for your sourcing budget.

Recession — 32% probability, $516K volume traded (Polymarket) Meaningful but not dominant. The bifurcation matters: recession doesn't kill peptide demand — it shifts it. Anecdotally (r/peptides community observation, not tracked data): gray-market vendor order volume tends to spike when compounder prices rise. If recession odds climb above 40% and compounder pricing follows, expect QSC/SRY to see demand pressure. Don't act on 32% — but watch the number.

Tariffs / China supply chain — structural risk, no Polymarket market today. A 25% tariff on Chinese goods would raise your gray-market vial cost 15–30% — a $40 vial becomes $46–52. No customs seizure data today, but the trade war trajectory is live. If you're sourcing from QSC, SRY, or GYC, the window for pre-tariff stocking may be shorter than you think.

SIGNAL VS. NOISE

SIGNAL: Orforglipron ACHIEVE-3 Phase 3 data in The Lancet. 9.2% weight loss, 2.2% HbA1c reduction, no food/timing restrictions, projected $149–399/month cash-pay (analyst estimate, not Lilly-confirmed). FDA decision early Q2 2026. $1.5B inventory staged. The $149 floor is the number that reshapes the market — that's the price point that undercuts compounded tirzepatide at most 503A pharmacies. Watch whether compounding prices drop in response to approval.

SIGNAL: 60–75% weight regain after stopping GLP-1s (48-study meta-analysis) paired against 3.7% regain on tirzepatide over 3 years. Not two separate data points — a decision framework. The drug works while you take it. Every person who starts is a potential lifetime customer. This is why the $70B → $201B market projection isn't hype.

SIGNAL: FDA's 30 warning letters to telehealth GLP-1 compounders. More enforcement in 6 months than the prior decade combined. Telehealth platforms that received letters face real compliance costs and potential supply disruption. If you're sourcing through a telehealth platform, verify their status now — don't wait for a supply gap.

SIGNAL: BPC-157 Phase 2 human trial now recruiting (NCT07437547). First registered human RCT for BPC-157 in history. Narrow indication, early stage, no data yet — but the compound is no longer purely animal-data territory. The regulatory conversation just changed.

NOISE: PharmaTher's PharmaPatch microneedle announcement for BPC-157/TB-500/GHK-Cu/KPV. A micro-cap (OTCQB: PHRRF) announced it's expanding its microneedle patch platform to peptides, explicitly citing RFK Jr.'s Joe Rogan comments as a tailwind. Early-stage R&D feasibility research — no human data, no IND, no timeline to market. The press release is designed to catch the RFK news cycle. The delivery science is real in concept; the product is years away at best. Zero near-term relevance to your sourcing decisions.

NOISE: RFK Jr.'s peptide reclassification as an immediate buying signal. A podcast appearance by a cabinet secretary is not a regulatory action. Half of r/peptides is acting like compounding is already legal again. It isn't. No Federal Register notice. No formal rule. The projected public comment timeline is an industry observer's estimate — not an FDA commitment. Act when the Federal Register drops, not before.

REGULATORY RADAR

FDA Warning Letters — March 3, 2026 30 telehealth companies received warning letters for misleading claims about compounded GLP-1 products. No company names publicly confirmed yet — monitor FDA.gov enforcement actions and your platform's communications. Primary violations: (1) implying compounded products are the same as FDA-approved drugs, (2) marketing under the telehealth firm's own brand without disclosing the compounded nature. Second wave since September 2025. Commissioner Makary: "It's a new era." This isn't slowing down.

RFK Jr. / Category 2 Peptide Reclassification The 19 peptides moved to Category 2 between late 2023 and December 2024: BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, Thymosin Alpha-1, Selank, Semax, GHRP-2, GHRP-6, KPV, Epitalon, DSIP, Melanotan II, AOD-9604, MOTS-C, PEG-MGF, Kisspeptin-10, and Cathelicidin LL-37. RFK Jr. wants ~14 back. Per the Orion Peptides analysis, the candidate list includes: BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, Thymosin Alpha-1, Semax, Selank, GHRP-2, GHRP-6, Epitalon, DSIP, PT-141, and Hexarelin. Note: different industry sources list slightly different candidate sets — this is the most detailed available as of today.

Current legal status: Category 2 = cannot be compounded by 503A/503B pharmacies. Gray-market research vendors operate outside this framework entirely (sold as "not for human use"). RFK's announcement changes nothing legally until a Federal Register notice is published. "Enforcement discretion" means FDA can choose not to prosecute even without a formal rule change — but it's not a written rule, and it can be reversed. If your 503A/503B compounder is offering BPC-157, ask them specifically how they're navigating Category 2 status.

Entera Bio EB613 (oral PTH/teriparatide) [Phase 3 — submitted March 4] Submitted streamlined Phase 3 protocol to FDA. Trial: 750 postmenopausal women, 12-month primary BMD endpoint (shortened from 24 months), using Next-Gen single-tablet EB613 via N-Tab® oral peptide delivery platform. Phase 3 initiation expected late 2026; topline data anticipated H2 2028. Relevant context: the oral peptide delivery science that gray-market vendors claim for nasal/oral BPC-157 is being validated in a regulated context — just for a different compound.

WHAT TO WATCH

Now — March 5: Check whether your telehealth GLP-1 platform received one of the 30 FDA warning letters. No public list confirmed yet. Action: Go to FDA.gov → Inspections, Compliance, Enforcement → Warning Letters → filter by date March 3, 2026. Also watch for any compliance notice or sudden repricing from your platform — that's the tell that they were hit.

March–April 2026: Watch for a Federal Register notice on peptide reclassification. This is the trigger that converts RFK's podcast statement into a legal change. When it drops, a 30-day public comment window opens — submit a comment if you want to influence the final rule. Until then: nothing has changed for compounders.

Early Q2 2026 (April–May): FDA decision on orforglipron. Lilly ships within ~1 week of approval. Watch for compounded tirzepatide pricing response — if oral orforglipron at $149/month gains traction, compounders face margin pressure. This could be good for your wallet.

Late 2026: CagriSema regulatory decision. REDEFINE 3 cardiovascular outcomes data. Retatrutide TRIUMPH Phase 3 readouts. MariTide MARITIME Phase 3 interim data. The next 9 months determine whether Lilly or Novo owns the obesity market through 2030.

The line to hold: The window between RFK's podcast signal and actual FDA reclassification is where the risk lives. Don't let a cabinet secretary's Joe Rogan appearance change your sourcing behavior before the Federal Register does.

Reply to this email with feedback — sourcing questions, compound requests, vendor intel. This newsletter runs on signal from the field.

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $5/month.